1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
Plasma IAPP-Autoantibody Levels in Alzheimer’s Disease Patients Are Affected by APOE4 Status
(
- Contribution to journal › Article
-
Mark
Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease
(
- Contribution to journal › Article
- 2022
-
Mark
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
(
- Contribution to journal › Article
- 2021
-
Mark
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
(
- Contribution to journal › Article
-
Mark
Time between milestone events in the Alzheimer's disease amyloid cascade
(
- Contribution to journal › Article
-
Mark
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
(
- Contribution to journal › Article
- 2020
-
Mark
Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cerebro-spinal fluid biomarker levels : phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease
(
- Contribution to journal › Article
- 2019
-
Mark
Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease
(
- Contribution to journal › Article